Open Access

Towards precision medicine for sepsis patients

Critical Care201721:11

https://doi.org/10.1186/s13054-016-1583-z

Published: 12 January 2017

The original article was published in Critical Care 2016 20:334

Keywords

Sepsis Hyperinflammation Immune suppression Cytokines Precision medicine Personalized Markers HLA-DR PD-1 PD-L1

Over the last decade it has become clear that the immunological response and clinical course in sepsis patients is too complex to simply regard it as ‘hyperinflammation-induced organ failure’. In contrast to the previous belief that patients mainly suffer from an exaggerated pro-inflammatory response, it has now become evident that a pro- and anti-inflammatory response are mounted simultaneously [1, 2]. Whether pro-inflammation or anti-inflammation is the overruling immune response may differ between patients and evolve over time in an individual patient [2], and this may explain why all previous clinical studies in sepsis patients using interventions to attenuate the immune response are negative [3]. Greater appreciation for the role of the dysregulated immune response is represented in the new definition of sepsis [4], defining sepsis as a life-threatening organ dysfunction caused by a dysregulated host response to infection.

One size does not fit all

Dozens of trials have convincingly demonstrated that inhibition of the immune response exerts no overall beneficial effects in the heterogeneous group of sepsis patients. Nevertheless, it is conceivable that a subgroup of patients may have benefited from inhibition of the immune response, but that in another subgroup of patients where immune suppression was the overriding immune dysregulation, no beneficial (or even detrimental) effects were evoked. Indeed, the interleukin (IL)-1 receptor blockade phase 3 trial published in 1997 [5] showed no effect of immune suppression with anakinra on mortality in patients suffering from severe sepsis. Based on new insights, a post-hoc analysis of this study performed 19 years later [6] identified that 5.6% of the study population presented with features of macrophage activation syndrome (sepsis with concurrent hepatobiliary dysfunction/disseminated intravascular coagulation). In this subgroup, mortality was 65% in the placebo-treated patients and 35% in the IL-1 receptor blockade patients (p = 0.0006) [6]. Naturally, this is a post-hoc analysis and no definitive conclusions can be drawn, but it does suggest that a specific subgroup of ‘hyperinflamed’ sepsis patients might benefit from inhibition of the immune response. The extent of this effect warrants further prospective study.

In contrast to this subgroup of patients that are hyperinflamed, observational data indicate that in a large proportion of sepsis patients immune suppression is the overriding immune dysregulation. For instance, sepsis patients are more likely develop infections with opportunistic bacteria or fungi [7] and up to 40% of patients show positive viral polymerase chain reactions (PCRs) indicating reactivation of latent viruses [8]. Furthermore, in a post-mortem study [9], profound suppression of immune cell function was found in tissue from patients that died of sepsis. Theoretically, pharmacological interventions aimed to stimulate recovery of this immune suppression might benefit this subgroup of patients.

Based on the above, it is clear that differentiation within sepsis patients is required to move this field forward, and immune phenotyping of sepsis patients may pave the way towards a more personalized approach, also called ‘precision medicine’.

Determining the immune status of sepsis patients

Various ways to gauge the immune status of sepsis patients have been described [2], and many more will likely emerge in the following years as a consequence of progress in our insight of which pathways play a role in the development of immune suppression in sepsis patients. For example, recent evidence points towards an important role for defects in energy metabolism in the impaired function of immune cells of septic patients [10]. As such, it can be envisioned that profiling of cellular metabolism provides a snapshot of the current immunological state of a septic patient and may be used to guide treatment. Furthermore, the programmed death 1 (PD-1) pathway appears to be of particular relevance in sepsis-induced immune suppression, and expression of PD-L1 (the ligand for PD-1) on the cell surface of monocytes is associated with risk stratification and mortality in septic patients [11]. As ex vivo addition of antibodies against PD-1 or PD-L1 restored function of monocytes, neutrophils, T cells, and natural killer (NK) cells [12], the data from clinical studies in the field of oncology that show that treatment with anti-PD-1/PD-L1 antibodies is feasible and safe [13] is of interest to the sepsis field. When these compounds are tested in immune suppressed sepsis patients, patient group enrichment by determination of monocyte PD-L1 expression is clearly of utmost relevance. Several other compounds (including interferon (IFN)γ, granulocyte macrophage colony-stimulating factor (GM-CSF), and IL-7) that stimulate the immune system through various pathways have already shown promising results in preclinical studies, and some even in small patient studies. For a fair chance of clinical success, it is pivotal that we do not make the same mistake again by advocating the use of these compounds in all sepsis patients, but rather use them in an immune-suppressed subgroup.

Up to now, two assays to determine the immune status in sepsis patients have been studied most extensively: ex vivo lipopolysaccharide (LPS)-induced cytokine production by leukocytes, and monocytic human leukocyte antigen-D related (HLA-DR) expression. The LPS-stimulated whole blood functional assay provides insight in the actual cell function, while determination of monocyte HLA-DR expression is more specific and at the single cell level. Drewry et al. recently compared these two methods head-to-head [14]. In 83 patients, of which over 60% suffered from septic shock, more than a quarter of the patients developed a secondary infection and in total 30% died. Blood samples were collected at three time points (days 1–2, days 3–4, and days 6–8 after sepsis diagnosis) and results were related to the development of secondary infections and mortality. Their main finding is that monocytic HLA-DR expression is a more accurate predictor for secondary infections and mortality than ex vivo LPS-induced cytokine production, and in their paper they describe several explanations for their finding. The authors did not calculate specificity and sensitivity, as a specific threshold would have to be chosen to designate the test as being “positive” or “negative”. Other researchers [15] have used values <8000 antibodies/cell as the diagnostic threshold for immunosuppression to investigate the effect of immunostimulatory therapy. Also, although it is tempting to speculate that the change in HLA-DR expression results in an increased risk to develop secondary infections and is directly related to the impaired outcome in these patients, the authors wisely refrain from such an interpretation as it could also be an epiphenomenon: more severely ill patients might be more likely to develop a secondary infection and have a higher mortality independent of HLA-DR expression. Of interest, the change in HLA-DR expression that was most associated with the development of secondary infections occurred between days 1–2 to days 3–4 (median change in HLA-DR of −934 antibodies/cell; p = 0.054). As the median time to onset of secondary infection was 9.4 (interquartile range (IQR) 5.5 to 10.0) days, this indicates that the change in HLA-DR expression preceded the diagnosis of the secondary infection. It appears likely that HLA-DR expression may even be lower in the days immediately preceding the development of a secondary infection, but because of the limited number of patients evaluated in each group, the current study was underpowered to detect this. Ultimately, it may be more informative to assess multiple immunological markers concurrently or monitor changes in markers over time.

In conclusion, it is important to emphasize that the aim of the present study was not to investigate cause-effect relationships, as it remains unclear if a decrease in HLA-DR expression is a true predictor or merely an epiphenomenon. Nevertheless, it shows that HLA-DR expression is more accurate in predicting secondary infections and death in sepsis patients than LPS-induced cytokine production. This indicates that HLA-DR expression may be used to identify whether or not a sepsis patient is in the immunosuppressive phase of their disease. This is of utmost importance, as it has become clear that undifferentiated immunomodulatory therapy in sepsis patients is bound to fail. It appears plausible that some patients may benefit from inhibition of the immune response, while others may benefit from stimulation of the immune response. Immunostimulatory treatment should only be offered to those patients who suffer from a suppressed immune system and, for now, monocytic HLA-DR expression is the optimal marker to determine this.

Notes

Abbreviations

GM-CSF: 

Granulocyte macrophage colony-stimulating factor

HLA-DR: 

Human leukocyte antigen-D related

IFN: 

Interferon

IL: 

Interleukin

IQR: 

Interquartile range

LPS: 

Lipopolysaccharide

NK: 

Natural killer

PCR: 

Polymerase chain reaction

PD-1: 

Programmed death 1

PD-L1: 

Programmed death-ligand 1

Declarations

Acknowledgements

Not applicable.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Authors’ contributions

PP drafted the manuscript and MK critically revised the manuscript. Both authors read and approved the final manuscript.

Authors’ information

PP is an intensivist and Professor of Experimental Intensive Care Medicine. MK is a biomedical researcher and assistant professor at the Department of Intensive Care Medicine.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethical approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Intensive Care Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center
(2)
Radboud Center for Infectious Diseases (RCI)

References

  1. Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest. 2016;126(1):23–31.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers P. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med. 2013;187(12):1287–93.View ArticlePubMedGoogle Scholar
  3. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20(4):195–203.View ArticlePubMedGoogle Scholar
  4. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–10.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Opal SM, Fisher Jr CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997;25(7):1115–24.View ArticlePubMedGoogle Scholar
  6. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275–81.View ArticlePubMedGoogle Scholar
  7. Otto GP, Sossdorf M, Claus RA, Rodel J, Menge K, Reinhart K, Bauer M, Riedemann NC. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care. 2011;15(4):R183.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Walton AH, Muenzer JT, Rasche D, Boomer JS, Sato B, Brownstein BH, Pachot A, Brooks TL, Deych E, Shannon WD, et al. Reactivation of multiple viruses in patients with sepsis. PLoS One. 2014;9(2), e98819.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL. Jarman 2nd SD, Kreisel D, Krupnick AS, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594–605.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Cheng SC, Scicluna BP, Arts RJ, Gresnigt MS, Lachmandas E, Giamarellos-Bourboulis EJ, Kox M, Manjeri GR, Wagenaars JA, Cremer OL, et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat Immunol. 2016;17(4):406–13.View ArticlePubMedGoogle Scholar
  11. Shao R, Fang Y, Yu H, Zhao L, Jiang Z, Li CS. Monocyte programmed death ligand-1 expression after 3–4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit Care. 2016;20(1):124.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Patera AC, Drewry AM, Chang K, Beiter ER, Osborne D, Hotchkiss RS. Frontline Science: defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol. 2016.Google Scholar
  13. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–61.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Drewry AM, Ablordeppey EA, Murray ET, Beiter ER, Walton AH, Hall MW, Hotchkiss RS. Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study. Crit Care. 2016;20(1):334.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640–8.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016